DAWN
Price
$11.16
Change
+$3.72 (+50.00%)
Updated
Feb 3 closing price
Capitalization
1.14B
33 days until earnings call
Intraday BUY SELL Signals
ERAS
Price
$10.59
Change
+$8.14 (+332.24%)
Updated
Feb 3 closing price
Capitalization
3.28B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DAWN vs ERAS

Header iconDAWN vs ERAS Comparison
Open Charts DAWN vs ERASBanner chart's image
Day One Biopharmaceuticals
Price$11.16
Change+$3.72 (+50.00%)
Volume$1.9M
Capitalization1.14B
Erasca
Price$10.59
Change+$8.14 (+332.24%)
Volume$5.67M
Capitalization3.28B
DAWN vs ERAS Comparison Chart in %
DAWN
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DAWN vs. ERAS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DAWN is a Hold and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (DAWN: $11.16 vs. ERAS: $10.59)
Brand notoriety: DAWN and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DAWN: 68% vs. ERAS: 94%
Market capitalization -- DAWN: $1.14B vs. ERAS: $3.28B
DAWN [@Biotechnology] is valued at $1.14B. ERAS’s [@Biotechnology] market capitalization is $3.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DAWN’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 0 green FA rating(s).

  • DAWN’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 0 green, 5 red.
According to our system of comparison, both DAWN and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DAWN’s TA Score shows that 3 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • DAWN’s TA Score: 3 bullish, 6 bearish.
  • ERAS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than DAWN.

Price Growth

DAWN (@Biotechnology) experienced а -9.49% price change this week, while ERAS (@Biotechnology) price change was +0.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

DAWN is expected to report earnings on Mar 09, 2026.

ERAS is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.28B) has a higher market cap than DAWN($1.15B). ERAS YTD gains are higher at: 184.543 vs. DAWN (19.742). ERAS has higher annual earnings (EBITDA): -131.32M vs. DAWN (-162.07M). DAWN has more cash in the bank: 452M vs. ERAS (288M). DAWN has less debt than ERAS: DAWN (2.89M) vs ERAS (48.3M). DAWN has higher revenues than ERAS: DAWN (134M) vs ERAS (0).
DAWNERASDAWN / ERAS
Capitalization1.15B3.28B35%
EBITDA-162.07M-131.32M123%
Gain YTD19.742184.54311%
P/E RatioN/AN/A-
Revenue134M0-
Total Cash452M288M157%
Total Debt2.89M48.3M6%
TECHNICAL ANALYSIS
Technical Analysis
DAWNERAS
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
DAWN
Daily Signal:
Gain/Loss:
ERAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DNSVX16.840.11
+0.66%
Dunham Small Cap Value N
AALRX27.690.02
+0.07%
American Beacon Large Cap Value R6
PIEQX21.12N/A
N/A
T. Rowe Price International Eq Index
FTVNX33.13-0.39
-1.16%
FullerThaler Behav Md-Cp Val Investor
PMBMX37.68-1.00
-2.59%
Principal MidCap R3

DAWN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DAWN has been loosely correlated with OCUL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if DAWN jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DAWN
1D Price
Change %
DAWN100%
-2.96%
OCUL - DAWN
48%
Loosely correlated
-6.99%
IMTX - DAWN
46%
Loosely correlated
-0.40%
NUVL - DAWN
45%
Loosely correlated
+2.12%
BEAM - DAWN
44%
Loosely correlated
-0.11%
ERAS - DAWN
44%
Loosely correlated
-0.24%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.24%
RVMD - ERAS
57%
Loosely correlated
-1.22%
IRON - ERAS
50%
Loosely correlated
-1.17%
IDYA - ERAS
48%
Loosely correlated
+0.50%
ACLX - ERAS
48%
Loosely correlated
-0.01%
NRIX - ERAS
48%
Loosely correlated
-1.76%
More